InMed Expects Mentari Merger to Close November 6, Nasdaq Trading as MTRI to Begin November 9
InMed’s merger with Mentari Therapeutics is expected to close on November 6, 2026, pending final conditions. Governed by an amended agreement dated May 19, 2026, the combined entity will begin trading on The Nasdaq Capital Market under the name Mentari Therapeutics, Inc. and the ticker symbol MTRI on November 9, 2026. The new common stock will be assigned CUSIP number 587157108 and ISIN number US5871571080. Additionally, eligible shareholders of record as of November 5, 2026, are expected to receive one contingent value right per share under a forthcoming agreement.
InMed said its previously announced merger with Mentari Therapeutics, Inc. is expected to close on November 6, 2026, subject to the satisfaction or waiver of the remaining closing conditions.
The transaction is governed by an amended agreement and plan of merger and reorganization dated May 19, 2026. The agreement involves the company, Mentari Therapeutics, Indigo Merger Sub Corp. and Indigo Merger Sub II, LLC.
At the commencement of trading on November 9, 2026, the company’s common stock is expected to begin trading on The Nasdaq Capital Market under the name Mentari Therapeutics, Inc. and the new ticker symbol MTRI. The shares are also expected to have a new CUSIP number of 587157108 and a new ISIN number of US5871571080.
In connection with the merger, the company expects to enter into a contingent value rights agreement on or before the merger’s closing date. Under that arrangement, shareholders of record as of the close of business on November 5, 2026 are expected to receive one contingent value right for each outstanding common share of the company.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.